EP1599223A4 - Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins - Google Patents

Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins

Info

Publication number
EP1599223A4
EP1599223A4 EP04708279A EP04708279A EP1599223A4 EP 1599223 A4 EP1599223 A4 EP 1599223A4 EP 04708279 A EP04708279 A EP 04708279A EP 04708279 A EP04708279 A EP 04708279A EP 1599223 A4 EP1599223 A4 EP 1599223A4
Authority
EP
European Patent Office
Prior art keywords
immunogenic
ligand
fusion proteins
antigenic molecule
molecule complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04708279A
Other languages
German (de)
French (fr)
Other versions
EP1599223A2 (en
Inventor
Pramod K Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut Health Center
Original Assignee
University of Connecticut Health Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut Health Center filed Critical University of Connecticut Health Center
Publication of EP1599223A2 publication Critical patent/EP1599223A2/en
Publication of EP1599223A4 publication Critical patent/EP1599223A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
EP04708279A 2003-02-04 2004-02-04 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins Withdrawn EP1599223A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44477303P 2003-02-04 2003-02-04
US444773P 2003-02-04
PCT/US2004/003865 WO2004069207A2 (en) 2003-02-04 2004-02-04 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins

Publications (2)

Publication Number Publication Date
EP1599223A2 EP1599223A2 (en) 2005-11-30
EP1599223A4 true EP1599223A4 (en) 2006-10-11

Family

ID=32850929

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04708279A Withdrawn EP1599223A4 (en) 2003-02-04 2004-02-04 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins

Country Status (4)

Country Link
EP (1) EP1599223A4 (en)
AU (1) AU2004208851A1 (en)
CA (1) CA2515123A1 (en)
WO (1) WO2004069207A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009233A2 (en) * 2005-07-18 2007-01-25 University Of Manitoba Peptide-based cytokine vaccines in the treatment of autoimmune and inflammatory diseases
CN109553688A (en) * 2012-12-05 2019-04-02 生控基因疫苗股份有限公司 Fusion protein as the immunogenicity reinforcing agent for inducing T cells with antigenic specificity reaction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
WO2001091787A1 (en) * 2000-06-02 2001-12-06 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
WO2001091787A1 (en) * 2000-06-02 2001-12-06 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HERZ J ET AL: "LRP: a multifunctional scavenger and signaling receptor.", THE JOURNAL OF CLINICAL INVESTIGATION. SEP 2001, vol. 108, no. 6, September 2001 (2001-09-01), pages 779 - 784, XP002378177, ISSN: 0021-9738 *
MORE S ET AL: "ACTIVATION OF CYTOTOXIC T CELLS IN VITRO BY RECOMBINANT GP96 FUSIONPROTEINS IRRESPECTIVE OF THE 'FUSED' ANTIGENIC PEPTIDE SEQUENCE", IMMUNOLOGY LETTERS, AMSTERDAM, NL, vol. 69, no. 2, 3 August 1999 (1999-08-03), pages 275 - 282, XP000974189, ISSN: 0165-2478 *

Also Published As

Publication number Publication date
EP1599223A2 (en) 2005-11-30
AU2004208851A1 (en) 2004-08-19
CA2515123A1 (en) 2004-08-19
WO2004069207A2 (en) 2004-08-19
WO2004069207A3 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
EP1594530A4 (en) Albumin fusion proteins
HK1195512A1 (en) Polysaccharide protein conjugate vaccines
IL176006A0 (en) Immunogenic peptide carrier conjugates and methods for producing the same
PL362324A1 (en) Artificial fusion proteins with reduced immunogenicity
IL202255A0 (en) Binding domain-immunoglobulin fusion proteins
EP1404178A4 (en) Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1663278A4 (en) Epo mimetic peptides and fusion proteins
IL166751A0 (en) Modified transferin-antibody fusion proteins
IL157993A0 (en) Molecular conjugates for use in cancer treatment and methods for the preparation thereof
AU2002300734A1 (en) Fusion protein having enhanced in vivo erythropoietin activity
AU2002339993A1 (en) P-amidobenzylethers in drug delivery agents
IL172094A0 (en) Polymeric conjugates and methods for the preparation thereof
AU2002364586A8 (en) Albumin fusion proteins
AU2002364587A8 (en) Albumin fusion proteins
EP1688439A4 (en) Fused protein composition
IL174479A0 (en) Hemiasterlin derivatives and uses thereof
AU2003228269A8 (en) Phosphorylated proteins and uses related thereto
EP1380593A4 (en) Soluble rage protein
ZA200206172B (en) Fusion protein having enhanced in vivo activity of erythropoietin.
IL153539A0 (en) Protein complexes and methods for the preparation thereof
HUP0303838A3 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
AU2002361390A8 (en) Anti-cd7 immunotoxin as fusion protein
WO2004069206A3 (en) Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
AU2002248467A1 (en) Vegf-d expression in brain cancer
AU2003227861A8 (en) Protein involved in cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050901

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060908

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061215